Journal of Clinical Case Reports

BP-C2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment: A Case of Advanced Inoperable Pancreatic Cancer

Abstract

Tarek Ibrahim, Stig Larsen, Nina Habib Lindkær Jensen and Steen Lindkær- Jensen

A successful example of use of a new regenerative substance BP-C2 in a patient with advanced inoperable pancreatic cancer before, during and after chemotherapy is described. The patient was subjected regularly to medical history review, physical examination, serum biochemistry, complete blood picture, computed tomography of the abdomen, and Quality-of-Life questionnaires (QoL). BP-C2 treatment was started and subsequently the condition of the patient improved. During this 26 weeks long treatment period, the patient tolerated FOLFIRINOX treatment well without any adverse effects (AE) and with improvement of her functional status. During the treatment with FOLFIRINOX and BP-C2 the sum diameter of the target lesions was reduced by 34.8%, the sum of non-target lesions were reduced by 86.2% and the number of non-target lesions fell from 4 to 1 and the AEs disappeared. C - reactive protein (CRP) was normalized and CA 19-9 reduced by 88% from baseline. QoL variables improved substantially. No neutropenia was observed after week 18 and all biochemical parameters were normalized at week 25. After discontinuation of BP-C2, recurrence of the tumors and AEs occurred A 19-9 and as well as QoL variables returned to baseline level. BP-C2 is a promising adjuvant treatment to the toxic chemotherapy regimens used in inoperable pancreatic cancer patients.